| Zinsser Analytic–Kohlberg Kravis Roberts: investment, 201609 acquisition of ILS Gmbh + Zinsser Analytic GmbH from Mr+Ms Zinsser by Gardner Denver |
2016-09-01 |
| Ziarco–Novartis: investment, 201612 acquisition €na by Novartis ANNOUNCED |
2016-12-16 |
| Zellkraftwerk–Canopy Biosciences: investment, 201904 acquisition of Zellkraftwerk GmbH by Canopy Biosciences |
2019-04-29 |
| Zedira–Germany (govt): grant, 201611– BMBF KMU-Innovativ funding €1.5m for 3y to support developm of ZED1227 in diabetic nephropathy |
2016-11-30 |
| Zavante Therapeutics–SEVERAL: investment, 201510 seed financing round |
2015-10-09 |
| Zavante Therapeutics–Nabriva: investment, 201807 acquisition upfront 8.2m Nabriva ordinary shares (=19.9% shareholding) + $97.5m milestones |
2018-07-24 |
| Yumda–Chemie.DE: investment, 201704 acquisition of Yumda GmbH by Chemie.DE Information Service GmbH |
2017-04-01 |
| Yukin Therapeutics–SEVERAL: investment, 201906 financing round €3.3m co-led by Advent France Biotechnology + Medicxi |
2019-06-04 |
| XtalPi–Swiss Investment Group: investment, 202009 financing round Series C totalling $318.8m incl existing + co-investor SIG |
2020-09-28 |
| XtalPi–SEVERAL: investment, 202009 financing round Series C $318.8m co-led by SoftBank Vision Fund 2 + PICC Capital + Morningside |
2020-09-28 |
| Xpand Biotechnology–Kuros: investment, 201612 merger acquisition of Xpand Biotechnology BV by Kuros Biosciences AG for up to 2.105m new Kuros shares |
2016-12-19 |
| Xigen–Instinctif Partners: public relations, 201701 service existent by Instinctif Partners |
2017-01-05 |
| Xenikos–MC Services: public relations, 201605 service existent for Xenikos BV by MC Services AG Düsseldorf |
2016-05-24 |
| Xencor–Selexis: cell line development, 201611– supply service strategic agreem for SUREtechnology for developm of multi-specific antibodies |
2016-11-03 |
| Xencor–Selexis: cell line development, 2011– supply service agreem for SUREtechnology for developm of multi-specific antibodies |
2011-01-01 |
| Xencor–JSR Corp: cell line development, 201802– four commercial licenses to use Selexis’ SUREtechnology for developm of bispecific antibodies |
2018-02-26 |
| Xeltis–SEVERAL: investment, 201711 financing round Series C €45m led by a global strategic investor + incl Ysios Capital + LSP + Kurma Partners et al |
2017-11-15 |
| X4 Pharmaceuticals–Arsanis: investment, 201811– reverse merger with former X4 owners to hold 70% + Arsanis to be renamed X4 ANNOUNCED |
2018-11-27 |
| WuXi PharmaTech–Ally Bridge Group: investment, 201702 existent investment of ABG |
2017-02-23 |
| Wise (IT)–SEVERAL: investment, 202010 financing round Series C €15m led by CDP Venture Capital SGR |
2020-10-01 |
| Wise (IT)–SEVERAL: investment, 201705 financing round Series B €6.5m led by Principia SGR + incl Atlante Ventures + HTGF + F3F + Antares |
2017-05-25 |
| Wilex–SEVERAL: investment, 201704– capital increase €4.99m with rights issue to existing shareholders incl dievini Hopp |
2017-04-24 |
| Wilex–SEVERAL: investment, 201604 capital increase €4.13m with 2.25m new shares at €1.84/share whereof >50% to Dievini Hopp |
2016-04-25 |
| Wilex–Hopp Group: investment, 201702– financing commitment of up to €10m by Dievini Hopp [not announced whether credit or investment] |
2017-02-06 |
| Werfen–Protagen: biomarker, 201608– license semi-excl for use of BICD2 biomarker for diagnosis of systemic sclerosis to Inova Diagnostics |
2016-08-11 |
| Wellington Partners–UTIMCO: investment, 201907 final closing totalling €210m WPLS-V fund incl new investor UTIMCO |
2019-07-31 |
| Wellington Partners–Univ Texas: investment, 201907 final closing totalling €210m WPLS-V fund incl new investor Univ Texas/Texas A&M Investment Company |
2019-07-31 |
| Wellington Partners–Talanx: investment, 201907 final closing totalling €210m WPLS-V fund incl new investor Talanx |
2019-07-31 |
| Wellington Partners–SEVERAL: investment, 201907 final closing €210m WPLS-V fund incl investors KfW Capital + Talanx + UTIMCO + Univ Texas + EIB |
2019-07-31 |
| Wellington Partners–MC Services: public relations, 202001 service existent by MC Services |
2020-01-08 |
| Wellington Partners–Germany (govt): investment, 201907 final closing totalling €210m WPLS-V fund incl new investor KfW Capital |
2019-07-31 |
| Wellington Partners–EU (govt): investment, 201907 final closing totalling €210m WPLS-V fund incl exisiting investor EIB/EIF |
2019-07-31 |
| Wellington Partners–Consilium: public relations, 201907 service existent by CSC |
2019-07-31 |
| Wellington Partners–CMS: legal services, 201811 supply service legal advice by CMS for both lead investors HBM + Wellington of Adrenomed Series D |
2018-11-01 |
| Weizmann Institute–Bruker: MRI system, 201710 supply Biospec 15.2 Tesla USR preclinical UHF MRI system |
2017-10-18 |
| Waters–Heidrick & Struggles: recruitment services, 202007 supply service placement of Udit Batra as CEO of Waters |
2020-07-01 |
| Waters–Andrew Alliance: automated liquid handling technology, 201902–collab new solutions for LC-MS research |
2019-02-06 |
| Waters–Andrew Alliance: automated liquid handling technology, 201706– collab co-marketing semi-automated sample prep solution |
2017-06-01 |
| Warp Drive Bio–Revolution Medicines: investment, 201810 acquisition of Warp Drive Bio by Revolution Medicines |
2018-10-16 |
| VTU–KonValue: investment, 201810 acquisition of VTU Technology by KonValue Group from VTU Holding GmbH + renaming as Validogen GmbH |
2018-10-22 |
| Voluntis–SEVERAL: investment, 202011 capital increase €5.93m net €5.7m led by Debiopharm Innovation Fund |
2020-11-23 |
| Voluntis–Indigo (Eric Carreel): investment, 202011 capital increase totalling €5.93m incl €1m from existing + co-investor Indigo |
2020-11-23 |
| Voluntis–Debiopharm: investment, 202011 capital increase totalling €5.93m incl €3.92m from new + lead investor Debiopharm Innovation Fund |
2020-11-23 |
| Vivoryon–Trophic Communications: public relations, 201910 service existent by Trophic |
2019-10-08 |
| Vivoryon–SEVERAL: investment, 201910– public rights offering €30m–€70m incl Claus Chrisitansen + Den Danske Forskningsfond + T&W Holding + MorphoSys |
2019-10-08 |
| Vivoryon–MorphoSys: investment, 201910– public rights offering totalling €30m–€70m incl €15m but limited to max 19.98% holding from MorphoSys AG |
2019-10-08 |
| Vivoryon–MC Services: public relations, 201910 service existent by MC Services |
2019-10-08 |
| Vividion Therapeutics–SEVERAL: investment, 202102 financing round Series C $135m co-led by new investors Logos Capital + Boxer Capital |
2021-02-24 |
| Vividion Therapeutics–SEVERAL: investment, 201904 financing round Series B $82m led by new investor Nextech Invest |
2019-04-30 |
| Vividion Therapeutics–Nextech: investment, 201904 financing round Series B totalling $82m incl new + lead investor Nextech Invest |
2019-04-30 |
| Vivet Therapeutics–Ysios Capital: investment, 201705 financing round Series A totalling €37.5m incl co-investor Ysios Capital |
2017-05-04 |
| Vivet Therapeutics–SEVERAL: investment, 201705 financing round Series A €37.5m led by Novartis Venture Fund + Columbus Venture Partners |
2017-05-04 |
| Vivet Therapeutics–Roche: investment, 201705 financing round Series A totalling €37.5m incl co-investor Roche Venture Fund |
2017-05-04 |
| Vivet Therapeutics–Odlander Fredrikson: investment, 201705 financing round Series A totalling €37.5m incl co-investor HealthCap |
2017-05-04 |
| Vivet Therapeutics–Novartis: investment, 201705 financing round Series A totalling €37.5m incl co-lead investor Novartis Venture Fund |
2017-05-04 |
| Vivet Therapeutics–Kurma: investment, 201705 financing round Series A totalling €37.5m incl co-investor Kurma Partners |
2017-05-04 |
| Vivet Therapeutics–Columbus Venture Partners: investment, 201705 financing round Series A totalling €37.5m incl co-lead investor CVP |
2017-05-04 |
| Vivasure Medical–SEVERAL: investment, 201609 financing round Series C €16.2m led by LSP Health Economics Fund + co-led by Evonik VC |
2016-09-08 |
| ViroCyt–Sartorius: investment, 201607 acquisition valueing ViroCyt at $16m |
2016-07-15 |
| Viroad–Gilupi: diagnostic device, 2012 collab strategic partnership incl investment making Viroad largest shareholder of Gilupi |
2012-01-01 |
| Virion Biotherapeutics–Trophic Communications: public relations, 201811 service existent by Trophic |
2018-11-14 |
| ViraTherapeutics–MC Services: public relations, 201705 service existent by MC Services |
2017-05-30 |
| ViraTherapeutics–EMBL: investment, 201506 financing round Series A 1st closing totalling €3.6m co-led by BIVF + EMBL Ventures |
2015-06-23 |
| ViraTherapeutics–Boehringer: investment, 201809 acquisition of all remaining shares of ViraTby BI with total transaction value of €210m |
2016-08-01 |
| ViraTherapeutics–Boehringer: investment, 201506 financing round Series A 1st closing totalling €3.6m co-led by BIVF + EMBL Ventures |
2015-06-23 |
| ViraTherapeutics–Austria (govt): investment, 2015c financing €1.6m from FFG + aws seed financing programme |
2015-01-01 |
| ViraTherapeutics–Austria (govt): investment, 201506 financing round Series A 1st closing totalling €3.6m incl co-investor aws |
2015-06-23 |
| ViGeneron–WuXi PharmaTech: investment, 201911 financing round Series A incl co-lead investor WuXi AppTec |
2019-11-28 |
| ViGeneron–SEVERAL: investment, 201911 financing round Series A co-led by WuXi AppTec + Sequoia Capital China |
2019-11-28 |
| ViGeneron–Sequoia Capital: investment, 201911 financing round Series A incl co-lead investor Sequoia Capital China |
2019-11-28 |
| ViGeneron–MC Services: public relations, 201911 service existent media + investor relations by MC Services |
2019-11-28 |
| Vifor Pharma–Evotec: drug r+d, 201911– collab establishment 50/50 joint venture for nephrology treatments using NURTuRE biobank + PanHunter s/w |
2019-11-06 |
| Viewics–Roche: investment, 201711 acquisition of Viewics Inc by Roche |
2017-11-17 |
| Vico Therapeutics–Eurazeo: investment, 2019Q4–202007 financing round Series A totalling €27m incl co-investor Idinvest Partners |
2019-12-31 |
| Vico Therapeutics–Bellevue: investment, 2019Q4–202007 financing round Series A totalling €27m incl co-investor Pureos Bioventures |
2019-12-31 |
| VIB–Lipotype: mass spectrometry services, 2015– collab supply of shotgun lipidomics services by Lipotype to researchers at VIB |
2015-01-01 |
| Vesigen Therapeutics–SEVERAL: investment, 202007 financing round Series A $28.5m co-led by Leaps by Bayer + Morningside Ventures |
2020-07-22 |
| Vesigen Therapeutics–Bayer: investment, 202007 financing round Series A totalling $28.5m incl co-lead investor Leaps by Bayer |
2020-07-22 |
| Vesalius Biocapital–SEVERAL: investment, 201906 final closing of €120m Vesalius Biocapital III fund |
2019-06-25 |
| Vesalius Biocapital–SEVERAL: investment, 201705 first closing €65m of Vesalius Biocapital III fund |
2017-05-15 |
| Vertex–CRISPR Therapeutics: CRISPR technology, 201906– collab expansion $175m upfront + $825m milestones CRISPR for DMD + DM1 gene editing products |
2019-06-06 |
| Versum Materials–Merck (DE): investment, 201902– unsolicited all-cash offer at $48/share by Merck |
2019-02-27 |
| Versantis–SEVERAL: investment, 201909 financing round Series B CHF16m led by Swisscanto Invest by ZKB |
2019-09-18 |
| Versantis–SEVERAL: investment, 201703 financing round Series A CHF4.4m led by Redalpine Venture Partners |
2017-03-29 |
| Versantis–Halsin Partners: public relations, 201909 service existent by Halsin Partners |
2019-09-17 |
| Versameb–SEVERAL: investment, 201910 seed C financing round CHF6.4m bringing total capital raised to CHF11.8m |
2019-10-17 |
| Versameb–SEVERAL: investment, 201812 colsing of seed B financing round brining total capital raised to date to CHF5.3m |
2018-12-18 |
| Vera Therapeutics–Merck (DE): investment, 202011 Merck reveices 10% equity in Vera Tx as part of license deal for atacicept |
2020-11-09 |
| Vera Therapeutics–Merck (DE): atacicept, 202011– license for 10% equity in Vera + €605m milestones + royalties |
2020-11-09 |
| Ventech–SEVERAL: investment, 201803 first closing €140m of Ventech Capital V fund with €200m target size |
2018-03-07 |
| Velabs Therapeutics–SEVERAL: investment, 201906 financing round Series B €3m |
2019-06-27 |
| Velabs Therapeutics–Alytas Therapeutics: therapeutic antibodies, 202001– license excl for developm + commercialisation of Abs in field of senescence |
2020-01-07 |
| Vedere Bio–SEVERAL: investment, 201906 financing round Series A $21m |
2019-06-01 |
| Vedere Bio–Novartis: investment, 202009 acquisition $150m upfront + $130m milestones with some assets spun out before into Vedere BIo II |
2020-09-30 |
| VectivBio–WPP: public relations, 202001 service existent by Glover Park Group |
2020-01-07 |
| VectivBio–Versant Ventures: investment, 202001 1st financing round totalling $35m incl Versant Ventures |
2020-01-07 |
| VectivBio–Tekla Capital: investment, 202001 1st financing round totalling $35m incl Tekla Healthcare Investors |
2020-01-07 |
| VectivBio–SEVERAL: investment, 202010 crossover financing $110m from existing + new investors |
2020-10-15 |
| VectivBio–SEVERAL: investment, 202001 1st financing round $35m with Versant Ventures + Orbimed + Novo Holdings + Bpifrance et al. |
2020-01-07 |
| VectivBio–OrbiMed: investment, 202001 1st financing round totalling $35m incl OrbiMed |
2020-01-07 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo-2019.png){kind=logo}
Deal: Collaboration or Financing
![Picture [iito] Made Without Love 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-made-without-love.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
